To amend the Federal Food, Drug, and Cosmetic Act with respect to the requirements for the small business waiver from device fees related to annual establishment registration, and for other purposes.

On July 20, 2026, Rep. Scott Perry (R-PA-10) introduced HR9791, a bill to amend the Federal Food, Drug, and Cosmetic Act regarding the small business waiver from device fees related to annual establishment registration. The bill was referred to the House Committee on Energy and Commerce. It has zero cosponsors and no further action history beyond introduction.

The bill does not authorize or appropriate any funding. It is a regulatory amendment that would modify eligibility criteria for a fee waiver. The Congressional Budget Office would need to score any change in fee revenue, but no estimate is available. The mechanism is purely administrative — altering who qualifies for a waiver on FDA registration fees for medical device establishments.

No convergence exists with the provided presidential action on chemical manufacturing regulatory relief. That action addresses EPA stationary source regulations for chemical manufacturers, which is a different policy domain (Manufacturing/Energy) with no connection to FDA device registration fees for small businesses.

Structural winners and losers: None. The bill is too early-stage and narrow to identify specific companies. Medical device fee waivers affect small businesses, not publicly traded companies. Large medical device manufacturers ($MDT, $BSX, $SYK, $ABT) are not impacted because they do not qualify for small business waivers.

Timeline: The bill is at the earliest legislative stage. It must pass the House Energy and Commerce Committee, then the full House, then the Senate, and be signed by The President. No hearings or markups have been scheduled. Passage probability is low for a standalone bill with no cosponsors in a divided Congress.